Profile
Fernando Doñate worked as the Director of Preclinical Research at Proacta, Inc. from 2008 to 2010.
He also worked as the Associate Director of Biology at Attenuon, LLC.
Dr. Doñate earned a doctorate degree from the University of Missouri in 1994 and an undergraduate degree from Universidad Complutense de Madrid in 1988.
Former positions of Fernando Doñate
| Companies | Position | End |
|---|---|---|
| Attenuon, LLC | Corporate Officer/Principal | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Chief Tech/Sci/R&D Officer | - |
Training of Fernando Doñate
| University of Missouri | Doctorate Degree |
| Universidad Complutense de Madrid | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
| Attenuon, LLC |
- Stock Market
- Insiders
- Fernando Doñate
